What is the current stock price of NervGen Pharma Corp. (NGENF)?

As of the latest market data, NervGen Pharma Corp. (NGENF) is trading at $3.95. The stock has seen a loss of -2.47% today.

Does NervGen Pharma Corp. (NGENF) pay a dividend?

Based on current data, NervGen Pharma Corp. does not have a confirmed active dividend policy.

What is the market cap of NervGen Pharma Corp.?

The current market capitalization of NervGen Pharma Corp. (NGENF) is approximately unavailable.

NGENF

NervGen Pharma Corp.·Healthcare

3.95

2.469%(−0.10)

Market Closed

5.74

45.316%(+1.79)

After Hours

Last Updated: — ET

52W L: $1.5052W H: $6.30

NGENF NEWS

globenewswire.com

Feb 11

NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company will present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC. Details of the presentation are as follows: Title: Emerging Therapies with Challenges and Opportunities for the Future Format: Presentation and Panel Discussion Date/Time: Sunday, February 15th, 2026, 4:15-5:00 pm ET Presenter: Adam Rogers, MD, President and Chief Executive Officer, NervGen Participants: Keith Tansey, MD, PhD, FASNR, FASIA, Director, Clinical Research at LifewardKristen Gill, OTD, OTR/L, CPAM, Food and Drug Administration (FDA) About Unite2Fight Paralysis' 20 th Annual Science and Advocacy Symposium Unite2Fight Paralysis is a nonprofit organization that exists to unite and empower the international spinal cord injury community to cure paralysis through advocacy, education, and support for research with the vision that every person has equal access to treatments that will restore health and independence after spinal cord injury.

globenewswire.com

Feb 9

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Company Profile

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-04-03

Beta

0.76

Websitewww.nervgen.com↗